Tevogen Bio (NASDAQ:TVGN) Cut to “Hold” at D. Boral Capital

Tevogen Bio (NASDAQ:TVGN) was downgraded by equities researchers at D. Boral Capital from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a research note on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $2.00.

Tevogen Bio Stock Performance

Tevogen Bio stock traded down $0.06 during trading on Wednesday, reaching $0.18. The company had a trading volume of 815,826 shares, compared to its average volume of 656,899. Tevogen Bio has a 12-month low of $0.18 and a 12-month high of $1.51. The stock’s 50 day moving average price is $0.31 and its two-hundred day moving average price is $0.53. The firm has a market capitalization of $36.32 million, a price-to-earnings ratio of -0.96 and a beta of -0.76.

Institutional Trading of Tevogen Bio

Large investors have recently added to or reduced their stakes in the stock. Bridgeway Capital Management LLC raised its position in Tevogen Bio by 66.7% in the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after purchasing an additional 33,000 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after buying an additional 152,572 shares in the last quarter. Finally, Deutsche Bank AG grew its stake in shares of Tevogen Bio by 304.1% in the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after buying an additional 130,738 shares in the last quarter.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.